Jupiter Neurosciences Inc stock is traded at $2.12, with a volume of 3,272. It is down -0.47% in the last 24 hours and down -25.87% over the past month. Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.
Previous Close:
$2.13
Open:
$2.10
24h Volume:
3,272
Relative Volume:
0.15
Market Cap:
$2.80M
Revenue:
$40,400
Net Income/Loss:
-$9.18M
P/E Ratio:
-
EPS:
-$0.2684
Net Cash Flow:
-$5.78M
1W Performance:
+3.41%
1M Performance:
-25.87%
6M Performance:
-92.21%
1Y Performance:
-97.92%
1-Day Range:
$2.01$2.13
1-Week Range:
$2.01$2.50
52-Week Range:
$2.01$103.50
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Name
Jupiter Neurosciences IncSector
HealthcareIndustry
BiotechnologyPhone
(561) 406-6154Address
1001 NORTH US HWY 1, JUPITER, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS